FOLH1 and prostate adenocarcinoma: A major challenge in the forthcoming years could consist in the efficient management of neuroendocrine-differentiated prostate adenocarcinoma [118], most often appearing secondary to treatment with AR inhibitors and displaying decreased or no expression of AR and PSMA [119].